We would love to hear your thoughts about our site and services, please take our survey here.
Should be a fairly quick P2 trial - only 32 patients , and a review after 20 .
Looks like they have funds to complete it alone then .
I guess much of the cost of these trials is front loaded , so now its running we could get a P2 readout whilst being 100% wholly owned .
Focusing on MDS in P2 . I wonder if they will also have an AML arm ?
Expect P1 data readout next .
New US sites coming online .
All good .
I like the title - but come on Faron - give us a bit more info lol !
Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments
https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-23-0350/730008/Bexmarilimab-activates-human-tumor-associated
Well , I just about got my top up at the placing price this morning .
Sp has settled down while we wait for the next price of news .
Faron now clear to progress their plans into next year .
The upcoming ASH poster involves Naval Daver - our enthusiastic and influential man at MD Anderson .
LLS have also recently announced that they are increasing the amount that they will be funding research programs in 2024 .
And I re-read the RNS about what they planned to do with the 7.1 million euros.
Onwards and upwards .
Should the Company raise approximately EUR 6.0 million, the Company would have sufficient funding for its working capital needs into Q1 2024. The Company intends to use the proceeds of the Placing for the following:
· BEXMAB program (approx. 29%)
· Initiation of Phase 2
· Opening 5 new sites in the US
· Full Phase 1 data readout
· Bexmarilimab CMC (approx. 38%)
· First commercial scale production batch of Bex (2000 L)
· Other clinical development (approx. 5%)
· G&A (approx. 15%)
· Financing (approx. 13%)
Yes and I could yesterday too , eventually .
I see that as a good sign , not a ramp or anything .
In fact , when I started buying in here a while a go it was similar .
I've got holdings that on most days you can't get a quote to sell , but you can buy as much as you want .
Yep I can't get a quote for even 500 shares.
Similar to this morning .
Whatever the rumour , someone is definitely wanting these shares at the moment .
I had some more this morning , but took a long time to get them.
£59m Mcap - ok, its getting bigger , but still a minnow in these waters .
Indeed . It wasn't easy , but over the last year , I've managed to get my average down to 6.4p .
Got myself a nice round number of shares now , which I have no intention of selling until we are either bought out , or see true value - how ever long it takes .
But the trader in me needed a fix , so I actually had a pile this morning too . Should have done it earlier , but the momentum here is relentless . Well done all those that have endured the dark days - finally we are getting back on track .
Hi TC .
Looking back , it always seems likely that they are about to do some kind of deal , but it never happens.
I really think that a deal is coming , but there again , if they do fundraise for a P2 Bexmab trial , which is possible as it will be a small number of patients ( 70 odd I think was mentioned) , I still think it would be worthwhile .
The full P1 data readout will be coming soon .
Either way , a P2 will happen , and odds on it will be a success .
Markku has built up a very strong team , has the backing of some big players , and seems super confident and positive .
5 new sites in the US to support Bexmab - which will accelerate any P2 timetable .
SP is back to placing price this week . Not sure if there is a distressed seller over on Nas , or another reason , but I just see it as a good top up level , should i have any free funds .
As always , best of luck .
Yes , indication that there is no pessimism here as to the reasons behind this raise .
Shame in a way as I was hoping to top up at a discount .
Give it a month or two , looking back , it may well prove to be at a discount .
Now we can focus on Bexmab , the amazing data , and all the positioning within the company for future expansion .
7.1 million euros raised .
at approx £2.50 odd .
They now have enough to see them through to Q2 2024 - crucial time so at least we know they are funded .
Timo and other big investors all still 100% behind this .
Sp at these levels isn't a worry , most LTHs know how likely a success is now , so just sit tight or add if you want .
Now lets crack on .
And I do like the confidence of commercial production . Bexmab leading to accelerated market approval must surely be nailed on by now .
Should the Company raise approximately EUR 6.0 million, the Company would have sufficient funding for its working capital needs into Q1 2024. The Company intends to use the proceeds of the Placing for the following:
· BEXMAB program (approx. 29%)
· Initiation of Phase 2
· Opening 5 new sites in the US
· Full Phase 1 data readout
· Bexmarilimab CMC (approx. 38%)
· First commercial scale production batch of Bex (2000 L)
· Other clinical development (approx. 5%)
· G&A (approx. 15%)
· Financing (approx. 13%)
The use of proceeds from the Placing above is based on streamlined focus on BEXMAB study and resulted in significant cost savings.
AS expected by many . At least we will now have sufficient funds to keep Bexmab on track , and allow negotiations to conclude . Don't expect much of a discount off SP , but will probably have a top up if its much below todays price .
Like CB says , it's a means to an end , and at this juncture , we only need a few months really to have everything tied up .
This smells like a 'keep a lid on the SP' RNS . Its of no consequence materially - lots of engineering work decisions going on on a daily basis I'm sure , that we don't need to be bothered with . Let see what happens after the 26th .